The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index; 12 of the 30 sources its claims cite were checked for support.
An Autologous Macrophage‐Based Phenotypic Transformation‐Collagen Degradation System Treating Advanced Liver Fibrosis
Open accessAbstract
In advanced liver fibrosis (LF), macrophages maintain the inflammatory environment in the liver and accelerate LF deterioration by secreting proinflammatory cytokines. However, there is still no effective strategy to regulate macrophages because of the difficulty and complexity of macrophage inflammatory phenotypic modulation and the insufficient therapeutic efficacy caused by the extracellular matrix (ECM) barrier. Here, AC73 and siUSP1 dual drug‐loaded lipid nanoparticle is designed to carry milk fat globule epidermal growth factor 8 (MFG‐E8) (named MUA/Y) to effectively inhibit macrophage proinflammatory signals and degrade the ECM barrier. MFG‐E8 is released in response to the high reactive oxygen species (ROS) environment in LF, transforming macrophages from a proinflammatory (M1) to an anti‐inflammatory (M2) phenotype and inducing macrophages to phagocytose collagen. Collagen ablation increases AC73 and siUSP1 accumulation in hepatic stellate cells (HSCs) and inhibits HSCs overactivation. Interestingly, complete resolution of liver inflammation, significant collagen degradation, and HSCs deactivation are observed in methionine choline deficiency (MCD) and CCl 4 models after tail vein injection of MUA/Y. Overall, this work reveals a macrophage‐focused regulatory treatment strategy to eliminate LF progression at the source, providing a new perspective for the clinical treatment of advanced LF.
Overview
CoChat Summary
TL;DR
This paper presents MUA/Y, a dual-drug lipid nanoparticle coated with MFG-E8, to treat advanced liver fibrosis by both reprogramming macrophages and breaking down the collagen-rich ECM barrier. In mouse MCD and CCl4 fibrosis models, the system reduced inflammation, collagen deposition, and hepatic stellate cell (HSC) activation, with the authors stating collagen content was not significantly different from the normal group after treatment.
Key findings
- MFG-E8 shifted macrophages from a proinflammatory to an anti-inflammatory state: in LPS-primed RAW264.7 cells, M1 macrophages decreased from 87.2% to 54.9% and M2 macrophages increased to 38.3% after MFG-E8 administration.
- In primary liver macrophages from MCD-fed mice, MFG-E8 induced phenotypic transformation in only 26.5% of macrophages at 5 weeks and 16.1% at 9 weeks, showing reduced responsiveness in advanced fibrosis.
- The final formulation MUA/Y had a particle size of about 175 nm and strong stability in PBS and 10% FBS; the AC73 release was about 46% at 72 h at pH 7.4 and about 65% at 72 h at pH 5.0.
- In the MCD model, MUA/Y reduced hydroxyproline content, collagen deposition, and inflammatory cytokines back to normal levels, and the authors report no significant difference in collagen content from the normal group after treatment; similar antifibrotic effects were reported in the CCl4 model.
Methods
- The study designed an autologous macrophage-based lipid nanoparticle system, MUA/Y, carrying AC73 and siUSP1, with MFG-E8 adsorbed on the surface; MFG-E8 was intended to release in high-ROS fibrotic regions.
- In vitro work used RAW264.7 macrophages, HSC-T6 hepatic stellate cells, and coculture / transwell-style assays to test macrophage phenotypic switching, collagen phagocytosis, HSC activation, uptake, endosomal escape, and cytotoxicity.
- In vivo efficacy was tested by tail-vein injection in two advanced fibrosis mouse models: MCD-fed C57BL/6J mice for 63 days and a CCl4-induced model; outcomes included histology, hydroxyproline, inflammatory cytokines, transaminases, and marker expression.
Limitations
- The paper itself states that “the difficulty and complexity of macrophage inflammatory phenotypic modulation” and the “insufficient therapeutic efficacy caused by the extracellular matrix barrier” are major problems; these are presented as the motivation for the work rather than as study limitations.
- The text makes evident that much of the evidence is preclinical and relies on cell experiments and mouse models only; no human data are described.
- The text also shows that phenotypic conversion by MFG-E8 in primary macrophages was limited in advanced fibrosis (16.1% at 9 weeks), indicating incomplete responsiveness of diseased tissue.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
7 Valid · 4 Not valid · 12 Not checked · 130 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Inflammatory infiltration is one of the characteristics of LF and occurs in almost each fibrosis pathogenesis.[ 10 ]”
§ An Autologous Macrophage‐Based Phenotypic Transformation‐Collagen Degradation System Treating Advanced Liver Fibrosis > Introduction
What the sources say
- Partly supportedcites [10] A. T. Nguyen‐Lefebvre, A. Ajith, V. Portik‐Dobos, D. D. Horuzsko, A. S. Arbab, A. Dzutsev, R. Sadek, G. Trinchieri, A. Horuzsko, J. Clin. Invest. 2018, 128, 4870. 30137027 PMC6205377 sourceExperimental — accuracy not yet measured
Our copy supports the liver-fibrosis half of the claim: the introduction (unsectioned opening passage) states that bone-marrow-derived Ly6C hi macrophages 'predominate the macrophage population in the injured liver' and are 'inflammatory and critical for hepatic stellate cell (HSC) activation', and 'RLN drives macrophage phenotype switch' reports Ly6C hi pro-inflammatory macrophages dominating 'mouse chronically inflamed and fibrotic livers', with 'pRLN + miR-30a-5p synergistically reduces liver fibrosis' noting the CDAHFD model 'elicits hepatic steatosis, liver inflammation and fibrosis'. However, the sweeping generalization that inflammatory infiltration 'occurs in almost each fibrosis pathogenesis' (i.e., across fibrotic diseases generally) is nowhere asserted — our copy is confined to hepatic fibrosis (CCl4, NASH, human/mouse fibrotic liver), so that universal extension is not supported by this source. (LLM, conf=0.72)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In advanced liver fibrosis (LF), macrophages maintain the inflammatory environment in the liver and accelerate LF deterioration by secreting proinflammatory cytokines.”
§ An Autologous Macrophage‐Based Phenotypic Transformation‐Collagen Degradation System Treating Advanced Liver Fibrosis > Abstract
What the sources say
- Not checked — no full text of the sourcecites [11] a) A. P. Prakash Ramachandrana, M. A. Vernona, Proc. Natl. Acad. Sci. USA 2012, 109, E3186; 23100531 PMC3503234 b) F. Tacke, H. W. Zimmermann, J. Hepatol. 2014, 60, 1090. 24412603 source
- Not checked yetcites [12] M. R. C. Raja, V. Vinod Kumar, V. Srinivasan, S. Selvaraj, N. Radhakrishnan, R. Mukundan, S. Raghunandan, S. P. Anthony, S. Kar Mahapatra, J. Mater. Chem. B 2017, 5, 3511. 32264287 source
Checked before — its earlier verdict is held back until a new check runs.
- Partly supportedcites [13] A. Wree, M. D. Mcgeough, M. E. Inzaugarat, A. Eguchi, S. Schuster, C. D. Johnson, C. A. Peña, L. J. Geisler, B. G. Papouchado, H. M. Hoffman, A. E. Feldstein, Hepatology 2018, 67, 736. 28902427 PMC5849484 sourceExperimental — accuracy not yet measured
The Introduction and Results (page numbers unavailable) link activated macrophages and inflammatory cytokines to liver inflammation, and associate inflammatory macrophage infiltration with fibrosis in NLRP3-mutant mice. The paper does not establish that macrophages secrete the cytokines responsible for worsening fibrosis specifically at an advanced stage; its findings concern inflammation and fibrosis development in mice. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“AC73 is a cluster of differentiation‐147 (CD147)‐specific inhibitor,[ 24 ] that can act on activated HSCs that highly express CD147 to reduce their activation”
§ An Autologous Macrophage‐Based Phenotypic Transformation‐Collagen Degradation System Treating Advanced Liver Fibrosis > Introduction
What the sources say
- Could not verifycites [24] Z.‐g. F. L. W. H.‐y. C. J.‐l. P. S.‐j. W. J.‐j. Geng, Oncotarget 2016, 7, 9429. 26882566 PMC4891050 sourceExperimental — accuracy not yet measured
The Results and Discussion passages concern exosome-guided macrophage reprogramming and cutaneous wound healing, while the Experimental Section describes macrophage assays (page numbers unavailable). Searches for AC73, CD147, and hepatic stellate cells found no passage addressing the inhibitor or its effect on stellate-cell activation. (LLM, conf=0.76)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“inducing macrophages to phagocytose collagen”
§ An Autologous Macrophage‐Based Phenotypic Transformation‐Collagen Degradation System Treating Advanced Liver Fibrosis > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“complete resolution of liver inflammation, significant collagen degradation, and HSCs deactivation are observed in methionine choline deficiency (MCD) and CCl4 models after tail vein injection of MUA/Y.”
§ An Autologous Macrophage‐Based Phenotypic Transformation‐Collagen Degradation System Treating Advanced Liver Fibrosis > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
74 more claims
Create a free account to see all 153 claims and to verify the 4 references still open.
- Probably not a substantial claim. 6
- It may state two separate claims as one. 70
- The quote only partly states this claim. 1
Citations
Cites
Hepatic stellate cells as key target in liver fibrosis
Higashi, T., Friedman, S. L., & Hoshida, Y. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.007 · Cited by 1,485
Macrophage heterogeneity in liver injury and fibrosis
Tacke, F., & Zimmermann, H. W. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.12.025 · Cited by 1,061
Ramachandran, P., Pellicoro, A., Vernon, M. A., Boulter, L., Aucott, R. L., Ali, A., Hartland, S. N., Snowdon, V. K., Cappon, A., Gordon-Walker, T. T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119964109 · Cited by 1,001
Exosome‐Guided Phenotypic Switch of M1 to M2 Macrophages for Cutaneous Wound Healing
Kim, H., Wang, S. Y., Kwak, G., Yang, Y., Kwon, I. C., & Kim, S. H. (2019) · Advanced Science · doi:10.1002/advs.201900513 · Cited by 542
NLRP3 inflammasome driven liver injury and fibrosis: roles of IL-17 and TNF in mice
Wree, A., McGeough, M. D., Inzaugarat, M. E., Eguchi, A., Schuster, S., Johnson, C. D., Peña, C. A., Geisler, L. J., Papouchado, B. G., Hoffman, H. M., et al. (2018) · Hepatology · doi:10.1002/hep.29523 · Cited by 266
Deng, C., Zhang, Q., He, P., Zhou, B., He, K., Sun, X., Lei, G., Gong, T., & Zhang, Z. (2021) · Nature Communications · doi:10.1038/s41467-021-22454-z · Cited by 252
Safety profile of autologous macrophage therapy for liver cirrhosis
Moroni, F., Dwyer, B. J., Graham, C., Pass, C., Bailey, L., Ritchie, L., Mitchell, D., Glover, A., Laurie, A., Doig, S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0599-8 · Cited by 202
Hu, J., Zhao, Q., Kong, L.-Y., Wang, J., Yan, J., Xia, X., Jia, Z., Heimberger, A. B., & Li, S. (2021) · Science Advances · doi:10.1126/sciadv.abc2511 · Cited by 141
Hepatic macrophages act as a central hub for relaxin-mediated alleviation of liver fibrosis
Hu, M., Wang, Y., Liu, Z., Yu, Z., Guan, K., Liu, M., Wang, M., Tan, J., & Huang, L. (2021) · Nature Nanotechnology · doi:10.1038/s41565-020-00836-6 · Cited by 136
Huggins, D. N., LaRue, R. S., Wang, Y., Knutson, T. P., Xu, Y., Williams, J. W., & Schwertfeger, K. L. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0101 · Cited by 114
Research progress on the anti-hepatic fibrosis action and mechanism of natural products
Shan, L., Liu, Z., Ci, L., Shuai, C., Lv, X., & Li, J. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105765 · Cited by 111
Extracellular matrix-penetrating nanodrill micelles for liver fibrosis therapy
Fan, Q.-Q., Zhang, C.-L., Qiao, J.-B., Cui, P.-F., Xing, L., Oh, Y.-K., & Jiang, H.-L. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2019.119616 · Cited by 111
Self-citationThe innate immune receptor TREM-1 promotes liver injury and fibrosis
Nguyen-Lefebvre, A. T., Ajith, A., Portik-Dobos, V., Horuzsko, D. D., Arbab, A. S., Dzutsev, A., Sadek, R., Trinchieri, G., & Horuzsko, A. (2018) · Journal of Clinical Investigation · doi:10.1172/jci98156 · Cited by 104
MFG-E8 attenuates inflammation in subarachnoid hemorrhage by driving microglial M2 polarization
Gao, Y., Tao, T., Wu, D., Zhuang, Z., Lu, Y., Wu, L., Liu, G., Zhou, Y., Zhang, D.-D., Wang, H., et al. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113532 · Cited by 94
MAIT cell inhibition promotes liver fibrosis regression via macrophage phenotype reprogramming
Mabire, M., Hegde, P., Hammoutene, A., Wan, J., Caër, C., Sayegh, R. A., Cadoux, M., Allaire, M., Weiss, E., Thibault-Sogorb, T., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37453-5 · Cited by 93
Zhang, L.-F., Wang, X.-H., Zhang, C.-L., Lee, J., Duan, B.-W., Xing, L., Li, L., Oh, Y.-K., & Jiang, H.-L. (2022) · ACS Nano · doi:10.1021/acsnano.2c03858 · Cited by 92
Self-citationCUG-binding protein 1 regulates HSC activation and liver fibrogenesis
Wu, X., Wu, X., Ma, Y., Shao, F., Tan, Y., Tan, T., Gu, L., Zhou, Y., Sun, B., Sun, Y., et al. (2016) · Nature Communications · doi:10.1038/ncomms13498 · Cited by 88
Antiviral therapy in the palliative setting of HCC (BCLC-B and -C)
Reig, M., & Cabibbo, G. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.01.046 · Cited by 87
Nanoengineered mesenchymal stem cell therapy for pulmonary fibrosis in young and aged mice
Han, M.-M., He, X.-Y., Tang, L., Qi, L., Yang, M.-Y., Wang, Y., Xing, L., Jeong, J.-H., & Jiang, H.-L. (2023) · Science Advances · doi:10.1126/sciadv.adg5358 · Cited by 86
Self-citationFu, Z., Wang, L., Cui, H., Peng, J., Wang, S., Geng, J., Liu, J.-D., Feng, F., Song, F., Li, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6990 · Cited by 73
Bai, L., Kong, M., Duan, Z., Liu, S., Zheng, S., & Chen, Y. (2021) · Cell Death & Disease · doi:10.1038/s41419-020-03378-w · Cited by 73
Desert, R., Chen, W., Ge, X., Viel, R., Han, H., Athavale, D., Das, S., Song, Z., Lantvit, D., Cano, L., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000362 · Cited by 52
CD147 Promotes CXCL1 Expression and Modulates Liver Fibrogenesis
Shi, W., Ju, D., Li, H., Yuan, L., Cui, J., Luo, D., Chen, Z., & Bian, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041145 · Cited by 45
Sun, J., Ju, F., Jin, J., Wang, H. L., Li, Z. J., Sun, Y. C., Chen, Q. Z., Yang, Q. Q., Tan, J., & Zhou, Y. L. (2023) · Small · doi:10.1002/smll.202300326 · Cited by 41
Fang, W., Deng, Z., Benadjaoud, F., Yang, C., & Shi, G.-P. (2020) · Translational Research · doi:10.1016/j.trsl.2020.04.011 · Cited by 40
Wu, P., Luo, X., Wu, H., Zhang, Q., Dai, Y., & Sun, M. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120311 · Cited by 37
Remodeling of imbalanced extracellular matrix homeostasis for reversal of pancreatic fibrosis
Qi, L., Han, H., Han, M.-M., Sun, Y., Xing, L., Jiang, H.-L., Pandol, S. J., & Li, L. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2022.121945 · Cited by 36
Self-citationFan, R., Li, G., Yu, N., Chang, X., Arshad, T., Liu, W., Chen, Y., Wong, G. L., Jiang, Y., Liang, X., et al. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.03.005 · Cited by 26
Jain, I., Brougham-Cook, A., & Underhill, G. H. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.06.018 · Cited by 26
Wu, P., Luo, X., Sun, M., Sun, B., & Sun, M. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121492 · Cited by 25
ApAGP-fabricated silver nanoparticles induce amendment of murine macrophage polarization
Raja, M. R. C., Vinod Kumar, V., Srinivasan, V., Selvaraj, S., Radhakrishnan, N., Mukundan, R., Raghunandan, S., Anthony, S. P., & Kar Mahapatra, S. (2017) · Journal of Materials Chemistry B · doi:10.1039/c6tb02095j · Cited by 23
Du, Z., Wu, T., Liu, L., Luo, B., & Wei, C. (2022) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.02.025 · Cited by 13
Rosen, H. R., Ghany, M. G., Chung, R. T., et al. (2017) · Hepatology · doi:10.1002/hep.29361 · Cited by 12
Jia, H., Ding, L., Yu, A., Tang, W., Tang, S., Zhang, C., & Oupický, D. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.07.018 · Cited by 12
Yang, Y., Li, W., Liu, C., Liu, J., Yang, L., Yue, W., Yang, L., Xue, R., Zhang, K., Zhang, H., et al. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166754 · Cited by 12
Role of stabilin-1 in chronic liver tissue injury and repair
Shetty, S., Patten, D. A., Rantakari, P., Weston, C. J., Jalkanen, S., Salmi, M., & Adams, D. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30411-7 · Cited by 5
Han, X., Lv, Y., Li, Y., Deng, J., Qiu, Q., Liu, N., Zhao, S., & Liao, C. (2018) · Journal of International Medical Research · doi:10.1177/0300060518767550 · Cited by 5
The role of CD147 in liver injury: “The truth is in the details”
McLennan, S. V., Warner, F. J., & Shackel, N. A. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.11.029 · Cited by 3
Research works printed but not linked: 1
- Prakash Ramachandrana A. P., 2012, Proc. Natl. Acad. Sci. USA, 109
Cited by
Macrophages: Subtypes, Distribution, Polarization, Immunomodulatory Functions, and Therapeutics
Peng, M., Li, N., Wang, H., Li, Y., Liu, H., Luo, Y., Lang, B., Zhang, W., Li, S., Tian, L., et al. (2025) · MedComm · doi:10.1002/mco2.70304 · Cited by 121
Zhuang, P., Wu, Y., Chen, Y., Zhang, Y., Leboucher, C., Rosenholm, J. M., & Zhang, H. (2024) · Biomedical Technology · doi:10.1016/j.bmt.2024.09.005 · Cited by 48
Modulating Fibrotic Mechanical Microenvironment for Idiopathic Pulmonary Fibrosis Therapy
Li, X., Lin, Y., Han, M., Fang, Y., Xing, L., Jeong, J., & Jiang, H. (2024) · Advanced Materials · doi:10.1002/adma.202407661 · Cited by 39
Self-citationKey role of macrophages in the progression of hepatic fibrosis
Ran, J., Yin, S., Issa, R., Zhao, Q., Zhu, G., Zhang, H., Zhang, Q., Wu, C., & Li, J. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000602 · Cited by 31
Yuan, Y., Li, J., Chen, M., Zhao, Y., Zhang, B., Chen, X., Zhao, J., Liang, H., & Chen, Q. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.10.012 · Cited by 34
Metadata
- Authors
- Duan, B., Liu, Y., Li, X., Han, M., Yu, H., Hong, H., Zhang, L., Xing, L., & Jiang, H.
- Affiliations
- China Pharmaceutical University (CN)
- State Key Laboratory of Natural Medicines China Pharmaceutical University Nanjing 210009 China
- Corresponding author
- Jiang, Hu‐Lin
- Venue
- Advanced Science
- Publisher
- Wiley
- Published
- 2023-12-08
- Volume
- 11
- Issue
- 7
- Pages
- e2306899-e2306899
- ISSN
- 2198-3844 (ISSN-L)
- PMC
- PMC10870050
- OpenAlex
- W4389476564
- Semantic Scholar
- 950c63f129938a26f6ff2290a431e5661bf2ede3
- Cited by
- 38
- References
- 39
- Citations by year
- 2026: 10 · 2025: 17 · 2024: 10 · 2023: 1
- FWCI
- 6.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Advanced Science (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Key Research and Development Program of China (2022YFE0198400)
- National Natural Science Foundation of China (82020108029, 82073398)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- advanced liver fibrosis, collagen degradation, hepatic stellate cell activation, MFG-E8, reactive oxygen species-responsive release, liver inflammation
- MeSH terms
- Collagen, Humans, Liver Cirrhosis, Macrophages, Phenotype
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.